Impact of local treatment on overall survival of patients with metastatic prostate cancer: systematic review and meta-analysis

Arie Carneiro 1,2, Willy Baccaglini 2, Felipe P.A. Glina 3, Paulo P. Kayano 1, Victor M. Nunes 4, Oren Smaletz 5, Wanderley Marques Bernardo 4, Icaro Thiago de Carvalho 6, Gustavo Caserta Lemos 1

1 Departamento de Urologia, Hospital Israelita Albert Einstein, SP, Brasil; 2 Departamento de Urologia, Faculdade de Medicina do ABC, SP, Brasil; 3 Faculdade de Ciências Médicas, Universidade Metropolitana de Santos, SP, Brasil; 4 Centro Universitário Lusiada, Faculdade de Ciências Médicas de Santos, SP, Brasil; 5 Departamento de Oncologia, Hospital Israelita Albert Einstein, São Paulo, Brasil; 6 Departamento de Radioterapia, Hospital Israelita Albert Einstein, São Paulo, Brasil

ABSTRACT

Context: Currently, standard treatment of metastatic prostatic cancer (MPCa) is androgen-deprivation therapy (ADT). Recent studies suggested that local treatment of MPCa is related to increase of survival of those patients, as observed in other tumors.

Objective: To evaluate the impact of local treatment on overall survival and cancer specific survival in 3 and 5 years in patients with MPCa.

Materials and Methods: Systematic review and meta-analysis of population studies published at PubMed, Scielo, Lilacs, Cochrane and EMBASE databases until June 2016. Several large cohorts and Post-Roc studies were included, that evaluated patients with MPCa submitted to local treatment (LT) using radiotherapy (RDT), surgery (RP) or brachytherapy (BCT) or not submitted to local treatment (NLT).

Results: 34.338 patients were analyzed in six included papers, 31.653 submitted to NLT and 2.685 to LT. Overall survival in three years was significantly higher in patients submitted to LT versus NLT (64.2% vs. 44.5%; RD 0.19, 95% CI, 0.17-0.21; p<0.00001; I²=0%), as well as in five years (51.9% vs. 23.6%; RD 0.30, 95% CI, 0.11-0.49; p<0.00001; I²=97%). Sensitive analysis according to type of local treatment showed that surgery (78.2% and 45.0%; RD 0.31, 95% CI, 0.26-0.35; p<0.00001; I²=50%) and radiotherapy (60.4% and 44.5%; RD 0.17, 95% CI, 0.12-0.22; p<0.00001; I²=67%) presented better outcomes.

Conclusion: LT using RDT, RP or BCT seems to significantly improve overall survival and cancer-specific survival of patients with metastatic prostatic cancer. Prospective and randomized studies must be performed in order to confirm our results.

ARTICLE INFO

Keywords: Prostate; Survival; Radiation Oncology; Prostatic Neoplasms

Int Braz J Urol. 2017; 43: 588-99

Submitted for publication: August 23, 2016
Accepted after revision: October 01, 2016
Accepted after revision: October 24, 2016

INTRODUCTION

Radical prostatectomy (RP) has been reserved for patients with localized disease, and recently, its use was expanded to treat patients with locally advanced disease (1-3). Nowadays, it is discussed the impact of local treatment (LT) also for metastatic prostatic cancer (MPCA) in order to improve survival and time of response to androgen - deprivation therapy (ADT) and systemic pro-
gession of the disease (4-8). Standard treatment of patients with MPCa is single ADT, that has a overall survival of 42 months (9).

The treatment of the primary tumor of patients with metastatic disease has been established for some types of tumors. Two prospective and randomized studies showed a significant improvement of survival with cytoreductive nephrectomy associated to systemic treatment of patients with renal cell carcinoma (10, 11).

Also, current data show this benefit in relation to other tumors (ovary, gastrointestinal, among others) (12-14). However, until now, there is no study with evidence level 1 that demonstrates such benefit in relation to treatment of primary tumor in patients with MPCa. Recently published retrospective studies showed controversial results in relation to the benefits of LT associated to ADT on overall survival and cancer-specific survival (6, 15–18).

We decided to perform a systematic review and a meta-analysis in order to clarify the role of local treatment on overall survival in 3 and 5 years, as well on cancer-specific survival of patients with MPCa.

MATERIALS AND METHODS

Inclusion and Exclusion Criteria

We included case-control studies, big cohorts or clinical trials in English, Portuguese and Spanish, that presented data of patients with metastatic prostate cancer treated with LT (BCT and/or RDT and/or RP) or without LT (NLT) associated or not with ADT. The following aspects were analyzed: overall survival in 3 and 5 years, cancer-specific survival in 3 years and quality of life. Studies that did not separate results of treatment of high risk tumors and metastatic tumors were excluded.

Databases

Search was performed at MedLine, Lilacs and Embase until June, 26th, 2016. The terms included were: “((prostate OR prostatic) AND (cancer OR carcinoma OR tumour OR tumor OR neoplasm) AND (metastatic OR metastasis OR advanced OR “high risk” OR “lymph node” OR nodal)) OR (metastatic prostate cancer OR mPCa) AND (“local therapy” OR cytoreductive OR cytoreduction OR surgery OR prostatectomy OR “radiation therapy” OR radiotherapy OR Brachytherapy) AND (Castration OR Orchietectomy OR “Androgen-deprivation therapy” OR Androgen-deprivation OR “Gonadotropin-Releasing Hormone Agonists” OR “GnRHa treatment” OR “hormone therapy” OR “hormonal therapy” OR “Androgen deprivation” OR “chemohormonal therapy”) OR (Outcomes OR “Perioperative Outcome” OR “Survival Rate” OR “Neoplasm Recurrence”) AND (“prognosis/broad” [Filter] OR “therapy/broad” [Filter] OR “prognosis /narrow” [Filter]).”

Selection

Selection Process

Two authors singly performed the selection of articles according to title. If the theme was adequate to previous stablished criteria or if there was any doubt as the possibility of inclusion, the summary was read. Abstracts were analyzed by three authors and if considered adequate by at least two researchers, the whole article was obtained (19).

Checklist

SIGN checklists were used for comparative studies, using cohort and case-control studies.

Critic evaluation

Biases

For cohort studies, the analyzed biases included selection biases, performance biases, detection biases, and memory biases. In case-control studies it was analyzed selection biases, detection biases and memory biases.

Extraction of Results

Selected disclosure was overall survival in 3 and 5 years, and cancer-specific survival in 3 years. Sensitive analysis, when adequate, was performed for patients submitted to LT with or without ADT.

ANALYSIS

For meta-analysis, RevMan 5.3 software from Cochrane Library was used. For categorical variables it was used Cochran-Mantel-Haenszel test and for continuous the reverse variation test. Results were demonstrated by Forest Plot. Hetero-
geneity was considered acceptable when $i^2 < 50\%$, and in those cases it was used a fixed model. Heterogeneity was considered elevated when $i^2 \geq 50\%$, and in those cases it was used the randomic model. In case of two meta-analysis being analyzed, it was performed the Egger’s test, demonstrated by Funnel Plot. Studies that caused heterogeneity were removed and submitted to a new analysis.

RESULTS

Studies Selection

Our search was performed in June, 2016, and identified 19,958 articles, being 9 of grey area (using references of included articles). After the exclusion of 14,994 duplicate articles, 5,014 were selected for detailed analysis of summary, and 5,001 were excluded since they did not fulfill the inclusion criteria. After that, it was performed a detailed analysis of the remaining 28 articles and 16 were excluded due to inclusion criteria and 4 that did not include complete data of one of the targeted population.

In resume, 8 studies were included for systematic review and 6 for meta-analysis, with a total of 34,338 patients (Figure-1).

Studies characteristics

Seven cohorts were included from the articles (two were not included at meta-analysis since they did not provide adequate data) (20, 21) and one case-control study. No prospective and randomized study was identified (Table-1). For each study we made a detailed analysis of bias (Appendix 1).

Figure 1 - Studies Selection.
Synthesis of results

Association Between Overall Survival and Local Treatment in 3 and 5 Years Five studies showed higher overall survival in three years in patients with MPCa submitted to LT in relation to those treated by NLT with or without ADT (64.2% vs. 44.5%; RD 0.19, 95% CI, 0.17–0.21; p<0.00001; I²=0%) (Figure-2A). At sub-analysis, when we considered only patients submitted to ADT, we observed the same benefit on overall survival in three years of patients submitted to LT (63.6% vs. 43.1%; RD 0.19, 95% CI, 0.15–0.23; p<0.00001; I²=0%) (Figure-2B).

During the analysis of 5-year survival, the results of two studies showed benefits of LT in relation to NLT (51.9% vs. 47.9%; RD 0.20, 95% CI, 0.12–0.28; p<0.00001; I²=0%) (Figure-4A).

Four studies analyzed patients submitted to radiotherapy (BQT or RDT) and also showed benefit of LT in overall survival in 3 years (60.4% and 44.5%; RD 0.17, 95% CI, 0.12–0.22; p<0.00001; I²=67%) (Figure-6A). During sub-analysis, considering only patients submitted to ADT, overall survival in 3 years showed benefit in the group of patients submitted to BQT or RDT (62.5% vs. 43.0%; RD 0.20, 95% CI, 0.15–0.24; p<0.00001; I²=0%) (Figure-6B). Two studies showed higher cancer-specific survival after 3 years for the first group in relation to control (62.6% vs. 47.8%; RD 0.16, 95% CI, 0.10–0.21; p<0.00001; I²=0%) (Figure-6C).

### Table 1 - Characteristics of Studies.

| Article | Type of Study | Age - I/C (years) | PSA - I/C (mg/dL) | Staging | Intervention | Comparison | Follow-up | N° I | N° C | Outcome |
|---------|--------------|------------------|------------------|---------|--------------|------------|-----------|------|------|---------|
| Culp 2014(7) | CR | 64/72 | Interval | M1a,b,c | RP or BT | NLT | 5 years | 8185 | 8185 | OS, CSS |
| Antwi 2014(19)* | CR | Cutoff | Interval | M1a,b,c | RP or BT | NLT | 3 years | 7858 | 7858 | - |
| Fossati 2015(20)* | CR | 65/71 | 16/61 | M1a,b,c | RP or BT | NLT | 3 years | 8197 | 8197 | - |
| Satkunasivam 2015(21) | CR | 74/78 | 246.4/588.4 | M1a,b,c | RP or RT | NLT | 3 years | 4069 | 4069 | OS, CSS |
| Heidenreich 2015(22) | CC | 61/64 | 135.2/105.9 | M1b | RP | NLT | 3 years | 61 | 61 | OS, CSS |
| Cho 2016(23) | CR | 69 | 190 | M1b,c | RT | NLT | 3 years | 140 | 140 | OS |
| Lüppenberg 2016(24) | CR | 65/69 | 16/46.7 | M1a,b,c | RP, BT or RT | NLT | 3 years | 38929 | 15501 | OS |
| Rusthoven 2016(25) | CR | 66/69 | Interval | - | RT | NLT | 5 years | 6382 | 6382 | OS |

**CR** = cohort retrospective; **M1a** = metastasis in pelvic lymph nodes; **M1b** = bone metastasis; **M1c** = visceral metastasis; **RP** = radical prostatectomy; **RT** = radiotherapy; **BT** = brachytherapy; **NLT** = not submitted to local treatment; **OS** = overall survival; **CSS** = cancer survival specific.

* Studies included just in the systematic review.
Figure 2 - (A) Forest Plot - overall survival in 3 years of patients submitted to LT in relation to those treated with NLT with or without; (B) Forest Plot - sub-analysis of overall survival in 3 years of patients submitted to LT in relation to those treated with NLT with ADT; (C) Forest Plot - overall survival in 5 years of patients submitted to LT in relation to those treated with NLT.

| Study or Subgroup | LT | NLT | Risk Difference M-H, Fixed, 95% CI |
|-------------------|----|-----|----------------------------------|
| Cho 2016          | 26 | 38  | 0.27 [0.09, 0.44]                |
| Heidenreich 2015  | 21 | 23  | 0.14 [-0.05, 0.34]               |
| Lopenberg 2016    | 966| 1470| 0.18 [0.15, 0.20]                |
| Rusthoven 2016    | 334| 538 | 0.19 [0.15, 0.23]                |
| Satkunavisram 2015| 137| 242 | 0.23 [0.16, 0.29]                |
| Total (95% CI)    |    | 2311| 23834 100.0% 0.19 [0.17, 0.21] |
| Total events      | 1484| 10613|
| Heterogeneity: Chi² = 3.05, df = 4 (P = 0.55); I² = 0% |
| Test for overall effect: Z = 17.77 (P < 0.00001) |

Figure 3 - Forest Plot - cancer-specific survival in 5 years of patients submitted to LT in relation to those treated with NLT.

| Study or Subgroup | LT | NLT | Risk Difference M-H, Random, 95% CI |
|-------------------|----|-----|----------------------------------|
| Culp 2014         | 231| 373 | 0.39 [0.34, 0.44]                |
| Rusthoven 2016    | 242| 638 | 0.20 [0.16, 0.24]                |
| Total (95% CI)    |    | 911 | 13655 100.0% 0.30 [0.11, 0.49] |
| Total events      | 473 | 3218|
| Heterogeneity: Tau² = 0.02; Chi² = 33.03, df = 1 (P = 0.00001); I² = 97% |
| Test for overall effect: Z = 3.05 (P = 0.002) |
DISCUSSION

We are living a moment of transition in the profile of patients submitted to RP. In the 90’s, the great majority of those patients were those with low risk prostate cancer. Those with high risk disease were initially submitted to pelvic lymphadenectomy that would stop RP in the presence of a compromised lymph node. In the present, it is recommended to avoid unnecessary treatment of patients with low-risk PCa and for locally advanced disease, even with positive lymph nodes, multimodal treatment with RP and RDT can heal the great majority of patients, and these are the patients who would benefit more with a more radical approach (22).

Frequently, patients submitted to LT were younger, with better clinical conditions and more favorable in relation to GS and PSA at diagnosis, and the NLT group was not homogeneous in relation to the use of ADT. These facts highlight the discussion of the real difference of cancer-specific survival and mortality reached in every respective result. A series published by Rusthovem and cols (26) tried to eliminate these biases making a paired analysis with the same profile of patients in both groups, and also find a positive significance with the addition of local treatment for patients with MPCA.

It is known that the population of patients with MPCA is extremely heterogeneous and it is not possible to extrapolate the indication of local treatment to all patients. In order to try to identify the ideal candidate, Culp et al. (2014) (7) demonstrated an independent association among some variables (age higher than...
Figure 5 - (A) Forest Plot - cancer-specific survival after 3 years of patients submitted to LT and RP in relation to NLT group; (B) Funnel Plot - analysis of sensitivity of cancer-specific survival after 3 years of patients submitted to LT and RP in relation to NLT group; (C) Forest Plot - analysis of sensitivity of cancer-specific survival after 3 years of patients submitted to LT and RP in relation to NLT group.
70 years, Ct4 TNM disease, PSA>20ng/ML, high histological grade and pelvic lymphadenopathy) and an increase of cancer-specific mortality. Antwi et al. (2014) (21) showed that patients with MPCa with low differentiate tumors had a 46% higher risk of death due to all causes and 71% higher in relation to death due to PCa. In relation to the extension of the disease, mortality due to all causes was 52% higher for bone-restricted disease (M1b) and 88% higher for visceral disease (M1c) compared to the single involvement of non-pelvic lymph nodes (M1a). There was an increase of 70% of death due to PCa for M1b disease and a twice higher risk for M1c disease in relation to M1a.

Satkunasivam et al. (2015) (23) showed that advanced age, high levels of PSA, more aggressive high tumor, elevated CCI and bone irradiation less than 6 months of diagnosis are independent factors for the increase of cancer-specific mortality of MPCa patients, and those submitted to RP showed lower mortality when PSA ≤ 20ng/ml. Fossati et al. (2015) (20) found benefits of local treatment in patients with cancer-specific mortality in 3 years predicted to be up to 40%. NNT (number needed to treat) was constant in the
interval between 10% and 30%, and rose exponentially when the risk was above 40%. Löppem-berg et al. (2016) (27), based on some variables (age, initial PSA, CCI, Gleason Score-Gs and TNM AJCC) also developed a calculus in order to predict global mortality in 3 years of those patients, and concluded that risk over 70% did not add no time to survival with local treatment.

Several models of stratification of metastatic disease have been proposed and all consider visceral and lymph node metastasis important prognostic factors, highlighting the impact of the volume of the metastatic disease. According to SWOG (28), any metastatic lesion other than in the bones, regardless the number of lesions, must be considered high volume disease. Another criteria is the one adopted by the CHARTERED study (29), that considers high volume disease patients with visceral metastasis or ≥3 bone lesions of extra-axial bone lesion. This study showed that the combined treatment of QT and ADT was benefic in only patients with high volume disease (49 vs. 32.2 months). Cho et al. (30) also showed better prognosis of patients with metastasis restricted to bones in comparison to those with visceral disease. ECOG performance status, local of metastasis, extension of the disease and local therapy with RDT were related to increase of overall survival (ECOG PS 0-1 vs. 2-3, 3-yr OS 65% vs. 23%, p=0.004; M1b vs. other metastasis, 3-yr OS 52% vs. 3%, p=0.005; extension of the disease, single metastasis vs 2-4 metastasis vs. 5 metastasis 3-yr OS 57% vs. 41% vs. 28%, respectively, p=0.007). Therefore, the best candidate to local treatment is the young patient, without significant co-morbidities, and PSA lower than 20ng/ml and low volume metastatic disease (maybe restricted to bones).

Our analysis demonstrates the positive impact of local treatment on survival of patients with MPCa. Literature data show that more than one third of patients without local treatment will present severe local complications due to progression of primary tumor such as: number of hospitalizations, surgical procedures and consequently higher morbidity, with worsening of quality of life of patients (31-33). A case-control study suggests that RP lowers complication rates of urinary tract related to the progression of the disease, while one third of patients of control group presented lower urinary tract obstruction, hematuria or anemia (24). Morbidity and sequelae of local treatment still limit its indication in this scenario of no documented benefit. However, with evolution of technology, including robotic surgery, and more precise modalities of radiotherapy, the morbidity is being significantly reduced.

Surgical treatment of primary tumor is safe in locally advanced PCa (34, 35) and recent papers reproduced these results for metastatic disease. In the study of Cho et al. (2016) (30), 71% of patients treated with RDT received modulated intensity with the aid of helical tomography and none presented severe gastrointestinal or genital-urinary toxicity (grade 3–Radiation Therapy Oncology Group and EORTC criteria). Ten per cent of the RDT group presented hematologic complications grade 3 (Common Terminology Criteria for Adverse Events version 4.0).

However, Sooriakumaran et al. (2016) (25) published a multi-center study with 106 patients with MPCa submitted to RP (open or robotic). In their series, these therapeutic modalities were feasibly and safely performed in selected patients with MPCa, with general and peri-surgical specific complication rates similar to those with localized disease and locally advanced disease. Heidenreich et al. (2015) (24) showed no difference in the follow-up of patients submitted to RP (urinary incontinence and other post-surgical complications) in relation to those with high risk PCa. Complications due to local progression of disease with the necessity of surgical procedures correlated to GS at diagnosis (GS 8-10: 11 of 23, 47.8% vs. GS 7: 0 of 15, p=0.03).}

Our work has several limitations. Firstly, our systematic review and meta-analysis were based on retrospective population studies. Secondly, the few studies available in literature are heterogeneous (design, end-points) and they do not allow us to conclude adequately. In third place, not all NLT patients were treated with ADT, but at sub-analysis it was possible to compare LT+ADT vs. ADT alone. And, lastly, local treatment was performed in few patients, that frequently were in better conditions. Anyway, this article presents the best evidence on the subject at the moment. Some big centers already perform prospective and randomized trials in
order to evaluate the impact of local treatment on survival. However, it would be very important to also include quality of life analysis objectively with validated question forms (36). Such studies will be fundamental for the evaluation of the real benefit of LT of MPCa and which are the best candidates for such treatment.

CONCLUSIONS

Local treatment with RDT, RP or BQT seems to contribute significantly to increase overall survival of patients with MPCa. However, prospective and randomized studies are needed to corroborate our data and to identify which patient with MPCa is the ideal candidate for local treatment in a multimode approach.

ACKNOWLEDGEMENTS

Arie Carneiro and Willy Baccaglini contributed similarly as first authors

CONFLICT OF INTEREST

None declared.

REFERENCES

1. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181:956-62.
2. Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380:2018-27.
3. Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014;66:243-50.
4. Swanson G, Thompson I, Basler J, Crawford ED. Metastatic prostate cancer—does treatment of the primary tumor matter? J Urol. 2006;176:1292-8.
5. Sridharan S, Warde P. The importance of local control in high-risk locally advanced prostate cancer. Curr Oncol. 2012;19:S6-S12.
6. Shimabukuro T, Sakano S, Matsuda K, Kamiryo Y, Yamamoto N, Kaneda Y, et al. Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study. Int J Clin Oncol. 2013;18:62-7.
7. Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65:1058-66.
8. Carneiro A, Sasse AD, Wagner AA, Peixoto G, Kataguir A, Neto AS, et al. Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. World J Urol. 2015;33:1281-9.
9. James ND, Spears MR, Clarke NW, Dea-Naley DP, De Bon J, Gale J, et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67:1028-38.
10. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R; European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966-70.
11. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655-9.
12. Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004;5:219-28.
13. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248-59.
14. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1998;352:930-42.
15. Halabi S, Vogelzang NJ, Ou SS, Small EJ. The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials. J Urol. 2007;177:531-4.
16. Canby-Hagino ED, Swanson GP, Crawford ED, Basler JW, Hernandez J, Thompson IM. Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated? Curr Urol Rep. 2005;6:183-9.
17. Potosky AL, Harlan LC, Stanford JL, Gilliland FD, Hamilton AS, Albertsen PC, et al. Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 1999;91:1719-24.
18. Smith JA Jr, Bray WL. Re: Metastatic prostate cancer—does treatment of the primary tumor matter? Eur Urol. 2007;51:852-3.
19. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1-34.
20. Fossati N, Trinh QD, Sammon J, Sood A, Larcher A, Sun M, et al. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. Eur Urol. 2015;67:3-6.
21. Antwi S, Everson TM. Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: A population-based, propensity score analysis. Cancer Epidemiol. 2014;38:435-41.
22. Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A, et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol. 2011;59:832-40.
23. Satkunasivam R, Kim AE, Desai M, Nguyen MM, Quinn DI, Ballas L, et al. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis. J Urol. 2015;194:378-85.
24. Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol. 2015;193:832-8.
25. Soorakumar P, Karnes J, Stief C, Copsey B, Montorsi F, Hammerer P, et al. A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation. Eur Urol. 2016;69:788-94.
26. Rusthoven CG, Jones BL, Flag T, Crawford ED, Koshy M, Sher DJ, et al. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. J Clin Oncol. 2016;34:2835-42.
27. Löppenberg B, Dalela D, Karabon P, Sood A, Sammon JD, Meyer CP, et al. The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis. Eur Urol. 2016.
28. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368:1314-25.
29. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373:737-46.
30. Cho Y, Chang JS, Rha KH, Hong SJ, Choi YD, Ham WS, et al. Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis? PLoS One. 2016;11:e0147191.
31. Alemayehu B, Buysman E, Parry D, Becker L, Nathan F. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population. J Med Econ. 2010;13:351-61.
32. Won AC, Gurney H, Marx G, De Souza P, Patel M. Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int. 2013;112:E230-5.
33. Aus G, Hugosson J, Norlén L. Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent. J Urol. 1995;154:466-9.
34. Gakis G, Boorjian SA, Briganti A, Joniau S, Karazanashvili G, Karnes RJ, et al. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. Eur Urol. 2014;66:191-9.
35. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467-79.
36. Wagner AA, Cheng PJ, Carneiro A, Do virak O, Khosla A, Taylor KN, et al. Clinical Use of EPIC for Clinical Practice (EPIC-CP) to Assess Patient-Reported Prostate Cancer Quality-of-Life Following Robot-Assisted Radical Prostatectomy. J Urol. 2016.

Correspondence address:
Arie Carneiro, MD
Rua Iguatemi, 192 - 4 andar
São Paulo, SP, 01451-010, Brasil
Telephone: + 55 11 3168-2130
E-mail: arie.carneiro@einstein.br
### APPENDIX 1

| Sign Checklist for Cohort Studies | Sign Checklist for Case Control Studies |
|-----------------------------------|------------------------------------------|
| **Section 1: Internal Validity**   | **Section 1: Internal Validity**         |
| 1.1. The study addresses an appropriate and clearly focused question. | 1.1. The study addresses an appropriate and clearly focused question. |
| 1.2. The two groups being studied are selected from source populations that are comparable in all respects other than the factor under investigation. | 1.2. The cases and controls are taken from comparable populations. |
| 1.3. The study indicates how many of the people asked to take part did so, in each of the groups being studied. | 1.3. The same exclusion criteria are used for both cases and controls. |
| 1.4. The likelihood that some eligible subjects might have the outcome at the time of enrolment is assessed and taken into account in the analysis. | 1.4. What percentage of each group (cases and controls) participated in the study? |
| 1.5. What percentage of individuals or clusters recruited into each arm of the study dropped out before the study was completed. | 1.5. Comparison is made between participants and non-participants to establish their similarities or differences. |
| 1.6. Comparison is made between full participants and those lost to follow up, by exposure status. | 1.6. Cases are clearly defined and differentiated from controls. |
| 1.7. The outcomes are clearly defined. | 1.7. It is clearly established that controls are non-cases. |
| 1.8. The assessment of outcome is made blind to exposure status. If the study is retrospective this may not be applicable. | ASSESSMENT: |
| 1.9. Where blinding was not possible, there is some recognition that knowledge of exposure status could have influenced the assessment of outcome. | 1.8. Measures will have been taken to prevent knowledge of primary exposure influencing case ascertainment. |
| 1.10. The method of assessment of exposure is reliable. | 1.9. Exposure status is measured in a standard, valid and reliable way. |
| 1.11. Evidence from other sources is used to demonstrate that the method of outcome assessment is valid and reliable. | Y |
| 1.12. Exposure level or prognostic factor is assessed more than once. | Y |
| **CONFOUNDING:** | **Confounding:** |
| 1.13. The main potential confounders are identified and taken into account in the design and analysis. | 1.10. The main potential confounders are identified and taken into account in the design and analysis. |
| 1.14. Have confidence intervals been provided? | STATISTICAL ANALYSIS: |
| **Sections 2: Overall Assessment of the Study** | 1.11. Confidence intervals are provided. |
| 2.1. How well was the study done to minimise the risk of bias or confounding? | 2.1. How well was the study done to minimise the risk of bias? |

| 2012 | 2014 | 2015 | 2016 | 2017 | 2018 |
|------|------|------|------|------|------|
| Y | Y | Y | Y | Y | Y |
| Y | N | Y | N | N | N |
| D | D | D | D | D | D |
| N | N | N | N | N | N |
| A | A | A | A | A | A |
| Y | Y | Y | Y | Y | Y |
| D | D | D | D | D | D |
| N | N | N | N | N | N |
| A | A | A | A | A | A |
| Y | Y | Y | Y | Y | Y |
| D | D | D | D | D | D |
| N | N | N | N | N | N |
| A | A | A | A | A | A |
| Y | Y | Y | Y | Y | Y |
| Y | Y | Y | Y | Y | Y |

ASSESSMENT: CS

CONFOUNDING: Y

STATISTICAL ANALYSIS: Y

Sections 2: Overall Assessment of the Study: +